34 related articles for article (PubMed ID: 18342197)
1. The Imageable Genome.
Jané P; Xu X; Taelman V; Jané E; Gariani K; Dumont RA; Garama Y; Kim F; Del Val Gomez M; Walter MA
Nat Commun; 2023 Nov; 14(1):7329. PubMed ID: 37957176
[TBL] [Abstract][Full Text] [Related]
2. A prostate-specific antigen doubling time of <6 months is prognostic for metastasis and prostate cancer-specific death for patients receiving salvage radiation therapy post radical prostatectomy.
Jackson WC; Johnson SB; Li D; Foster C; Foster B; Song Y; Schipper M; Shilkrut M; Sandler HM; Morgan TM; Palapattu GS; Hamstra DA; Feng FY
Radiat Oncol; 2013 Jul; 8():170. PubMed ID: 23835115
[TBL] [Abstract][Full Text] [Related]
3. PSA doubling time for prediction of [(11)C]choline PET/CT findings in prostate cancer patients with biochemical failure after radical prostatectomy.
Giovacchini G; Picchio M; Scattoni V; Garcia Parra R; Briganti A; Gianolli L; Montorsi F; Messa C
Eur J Nucl Med Mol Imaging; 2010 Jun; 37(6):1106-16. PubMed ID: 20306038
[TBL] [Abstract][Full Text] [Related]
4. Imaging of prostate cancer local recurrences: why and how?
Rouvière O; Vitry T; Lyonnet D
Eur Radiol; 2010 May; 20(5):1254-66. PubMed ID: 19921202
[TBL] [Abstract][Full Text] [Related]
5. Freedom from a detectable ultrasensitive prostate-specific antigen at two years after radical prostatectomy predicts a favorable clinical outcome: analysis of the SEARCH database.
Chang SL; Freedland SJ; Terris MK; Aronson WJ; Kane CJ; Amling CL; Presti JC
Urology; 2010 Feb; 75(2):439-44. PubMed ID: 19819536
[TBL] [Abstract][Full Text] [Related]
6. Does early prostate-specific antigen doubling time (ePSADT) after radical prostatectomy, calculated using PSA values from the first detectable until the first recurrence value, correlate with standard PSADT? A report from the Shared Equal Access Regional Cancer Hospital Database Group.
Teeter AE; Presti JC; Aronson WJ; Terris MK; Kane CJ; Amling CL; Freedland SJ
BJU Int; 2009 Dec; 104(11):1604-9. PubMed ID: 19549124
[TBL] [Abstract][Full Text] [Related]
7. Inadequacy of prostate-specific antigen doubling time estimates calculated using an ultrasensitive assay of prostate-specific antigen for biochemical failure after radical prostatectomy.
Shimizu F; Matsuyama Y; Tominaga T; Ohashi Y; Fujime M
Urol Int; 2007; 79(4):356-60. PubMed ID: 18025856
[TBL] [Abstract][Full Text] [Related]
8. Death in patients with recurrent prostate cancer after radical prostatectomy: prostate-specific antigen doubling time subgroups and their associated contributions to all-cause mortality.
Freedland SJ; Humphreys EB; Mangold LA; Eisenberger M; Dorey FJ; Walsh PC; Partin AW
J Clin Oncol; 2007 May; 25(13):1765-71. PubMed ID: 17470867
[TBL] [Abstract][Full Text] [Related]
9. Body mass index and prostate specific antigen as predictors of adverse pathology and biochemical recurrence after prostatectomy.
Bañez LL; Sun L; Trock BJ; Han M; Partin AW; Aronson WJ; Terris MK; Presti JC; Kane CJ; Amling CL; Moul JW; Freedland SJ
J Urol; 2009 Aug; 182(2):491-6; discussion 496-8. PubMed ID: 19524974
[TBL] [Abstract][Full Text] [Related]
10. Prostate-specific antigen doubling time is a reliable predictor of imageable metastases in men with biochemical recurrence after radical retropubic prostatectomy.
Perlmutter MA; Lepor H
Urology; 2008 Mar; 71(3):501-5. PubMed ID: 18342197
[TBL] [Abstract][Full Text] [Related]
11. [PSA and follow-up after treatment of prostate cancer].
Benchikh El Fegoun A; Villers A; Moreau JL; Richaud P; Rebillard X; Beuzeboc P
Prog Urol; 2008 Mar; 18(3):137-44. PubMed ID: 18472065
[TBL] [Abstract][Full Text] [Related]
12. The role of testosterone replacement therapy following radical prostatectomy.
Khera M; Lipshultz LI
Urol Clin North Am; 2007 Nov; 34(4):549-53, vi. PubMed ID: 17983894
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
